Therapeutic Indications

Caspofungin is indicated for:

Fungal infections (Candida, Aspergillus) in febrile neutropaenia

Irrespective of gender only Adults (18 years old or older)

Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult patients.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-70 mg once daily

Invasive candidiasis

Irrespective of gender only Adults (18 years old or older)

Treatment of invasive candidiasis in adult patients.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-70 mg once daily

Invasive aspergillosis

Irrespective of gender only Adults (18 years old or older)

Treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50-70 mg once daily

Fungal infections (Candida, Aspergillus) in febrile neutropaenia

Irrespective of gender only Infants (40 days - 1 year old) , Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic paediatric patients.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 25-70 mg/m² once daily

Invasive candidiasis

Irrespective of gender only Infants (40 days - 1 year old) , Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Treatment of invasive candidiasis in adult or paediatric patients.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 25-70 mg/m² once daily

Invasive aspergillosis

Irrespective of gender only Infants (40 days - 1 year old) , Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Treatment of invasive aspergillosis in paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 25-70 mg/m² once daily